Amrutanjan Health Care Limited AI Stock Analysis
Want to see IN:AMRUTANJAN full AI Analyst Report?
Amrutanjan Health Care Limited (AMRUTANJAN) AI Stock Analysis
Amrutanjan Health Care Limited
(NSE:AMRUTANJAN)
The score is driven primarily by solid financial resilience and a very conservative balance sheet, offset by weak recent cash-flow conversion and negative free cash flow in 2026. Technicals are neutral-to-slightly positive short term but weaker over the longer trend, while valuation appears only moderately attractive with a low dividend yield.
Amrutanjan Health Care Limited (AMRUTANJAN) vs. iShares MSCI India ETF (INDA)
- Market Cap
- INR 14.82B
- Dividend Yield
- 0.96%
- Average Volume (3M)
- 1,917
- Price to Earnings (P/E)
- 25.9
- Beta (1Y)
- 0.76
- Revenue Growth
- 12.56%
- EPS Growth
- 1.03%
- Country
- India
- Employees
- 634
- Sector
- Healthcare
- Sector Strength
- 51
- Industry
- Drug Manufacturers - Specialty & Generic
Amrutanjan Health Care Limited Business Overview & Revenue Model
Company Description
Established in Chennai, India, in 1893, Amrutanjan Health Care Limited, formerly known as Amrutanjan Limited until its renaming in 2007, is a prominent manufacturer, supplier, and vendor of a broad array of wellness products. The company primarily op...
Amrutanjan Health Care Limited Financial Statement Overview
Summary
Profitability is steady with net margins around ~10.5%–11.5% (2023–2026) and revenue growth remains positive, but growth slowed in 2026 and margins have compressed versus 2021–2022. The balance sheet is a major strength with extremely low leverage, but cash-flow quality is a key concern given weak cash conversion and negative free cash flow in 2026.
Income Statement
64PositiveBalance Sheet
90Very PositiveCash Flow
40Negative| Breakdown | TTM | Mar 2026 | Mar 2025 | Mar 2024 | Mar 2023 | Mar 2022 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 5.29B | 5.03B | 4.51B | 4.21B | 3.80B | 4.05B |
| Gross Profit | 2.42B | 1.88B | 2.46B | 1.46B | 1.98B | 2.25B |
| EBITDA | 806.17M | 756.85M | 758.79M | 681.60M | 590.79M | 946.99M |
| Net Income | 572.91M | 579.18M | 508.35M | 449.73M | 398.35M | 671.89M |
Balance Sheet | ||||||
| Total Assets | 5.15B | 5.09B | 4.21B | 3.67B | 3.62B | 3.50B |
| Cash, Cash Equivalents and Short-Term Investments | 1.85B | 363.99M | 1.95B | 2.07B | 1.93B | 2.01B |
| Total Debt | 18.90M | 17.77M | 20.78M | 17.28M | 9.09M | 8.80M |
| Total Liabilities | 1.31B | 1.39B | 947.73M | 783.82M | 713.21M | 847.44M |
| Stockholders Equity | 3.84B | 3.70B | 3.27B | 2.88B | 2.91B | 2.65B |
Cash Flow | ||||||
| Free Cash Flow | 0 | -31.16M | 153.46M | 211.93M | 102.91M | 287.32M |
| Operating Cash Flow | 0 | 518.88M | 508.99M | 279.11M | 192.18M | 521.96M |
| Investing Cash Flow | 0 | -371.49M | -309.66M | 191.65M | -24.75M | -362.12M |
| Financing Cash Flow | 0 | -136.22M | -134.90M | -482.66M | -140.26M | -167.02M |
Amrutanjan Health Care Limited Technical Analysis
Price Trends
Market Momentum
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For IN:AMRUTANJAN, the sentiment is Neutral. The current price of 510.95 is above the 20-day moving average (MA) of 504.52, above the 50-day MA of 503.26, and below the 200-day MA of 534.04, indicating a neutral trend. The MACD of 3.06 indicates Negative momentum. The RSI at 53.51 is Neutral, neither overbought nor oversold. The STOCH value of 42.45 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Neutral sentiment for IN:AMRUTANJAN.
Amrutanjan Health Care Limited Peers Comparison
Overall Rating
IN:VENUSREM72Outperform
IN:MANKIND67Neutral
IN:PGHL64Neutral
IN:AMRUTANJAN62Neutral
IN:BLISSGVS61Neutral
IN:INDOCO43Neutral
Financial Indicators
| Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
| 72Outperform | INR 19.89B | 16.38 | ― | 0.67% | 20.22% | 73.03% | |
| 67Neutral | INR 1.10T | 49.05 | ― | 0.04% | 13.27% | 27.32% | |
| 64Neutral | INR 93.00B | 24.43 | ― | 3.77% | 16.05% | 23.81% | |
| 62Neutral | INR 14.94B | 25.86 | ― | 0.96% | 12.56% | 1.03% | |
| 61Neutral | INR 68.38B | 42.36 | ― | 0.23% | 24.87% | 46.37% | |
| Sector * | 51Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% |
| 43Neutral | INR 21.40B | 68.28 | ― | 0.09% | 10.75% | ― |
* Healthcare Sector Average
Performance Comparison
| Show on chart | Ticker | Company Name | Price | Change | % Change |
|---|---|---|---|---|---|
| IN:AMRUTANJAN | Amrutanjan Health Care Limited | 510.95 | -172.04 | -25.19% | |
| IN:BLISSGVS | Bliss Gvs Pharma Limited | 643.10 | 474.25 | 280.87% | |
| IN:INDOCO | Indoco Remedies Limited | 231.80 | -21.18 | -8.37% | |
| IN:MANKIND | Mankind Pharma Ltd. | 2660.00 | 440.00 | 19.82% | |
| IN:PGHL | Procter & Gamble Health Ltd. | 5602.70 | -58.88 | -1.04% | |
| IN:VENUSREM | Venus Remedies Limited | 1488.10 | 775.89 | 108.94% |
Amrutanjan Health Care Limited Corporate Events
Amrutanjan Health Care Releases September 2026 Investor Presentation
The company submitted its investor presentation for the quarter and half year ended September 30, 2026, under applicable securities-disclosure requirements. The release signals a focus on execution and stronger momentum, while providing investors wit...
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.
Date of analysis: Nov 17, 2026
